December 22, 2024 - 14:43

Proprietary mutual funds may seem appealing due to their personalized approach and tailored investment strategies, but they come with significant drawbacks that investors should carefully consider before making any commitments. These funds are often managed by financial institutions that have a vested interest in promoting their own products, which can lead to conflicts of interest.
Investors may find themselves facing higher fees and expenses compared to non-proprietary options. Additionally, the limited range of investment choices can restrict diversification, potentially increasing risk. The performance of proprietary funds may also be influenced by the institution’s marketing strategies rather than pure investment merit, making it challenging for investors to gauge true performance.
Before investing in proprietary mutual funds, individuals should conduct thorough research and weigh the potential benefits against the inherent risks. Consulting with a financial advisor can provide valuable insights and help investors make informed decisions tailored to their financial goals.
July 11, 2026 - 08:53
$9.5 Billion Focus Financial Network Expands to East Coast with Advisor Jennifer McDonaldMINNEAPOLIS, July 10, 2026 -- Focus Financial Network, a wealth management firm overseeing $9.5 billion in client assets, has expanded its footprint to the East Coast by adding financial advisor...
July 10, 2026 - 21:34
What the housing affordability bill means for buyers and sellersA new bipartisan bill in Congress, the 21st Century ROAD to Housing Act, is aiming to tackle the nation`s affordability crisis head-on. The legislation targets three main pain points: a severe...
July 10, 2026 - 09:43
MindRank Announces $52 Million Series B FinancingMindRank AI Ltd., a clinical-stage biotechnology company based in Hangzhou, China, has announced the completion of a $52 million Series B financing round. The funding was led by a group of...
July 9, 2026 - 18:12
Trending: Salesforce stock dips on Keybanc downgrade, AstraZeneca drug trial falls shortShares of Salesforce moved lower on Thursday after Keybanc analysts downgraded the stock, citing concerns about slowing growth and a challenging enterprise spending environment. The downgrade from...